Clinicopathological and Prognostic Value of NADPH Oxidase 2 (NOX2) in Primary Osteosarcoma.

Rong-Jin Lin,Zhen Huang,Sheng-Lin Wang,Hui Chen,Hong-Xiang Wei,Rong-Kai Shen,Liang-Yong Yang,Jian-Hua Lin
DOI: https://doi.org/10.1016/j.jos.2020.04.002
IF: 1.805
2020-01-01
Journal of Orthopaedic Science
Abstract:Background: Osteosarcoma is the most common primary malignant bone tumor, particularly among children and adolescents, and the prognosis of osteosarcoma patients remains poor. The NADPH oxidase 2 (NOX2) has been found over-expressed in several human cancers, and closely associated with poor prognosis. Meanwhile the role of NOX2 in osteosarcoma patients has not been reported. This study aimed to investigate the clinicopathological and prognostic significance of NOX2 in osteosarcoma patients. Methods: Immunohistochemistry (IHC), western blot (WB) and reverse transcription-quantitative po-lymerase chain reaction (RT-qPCR) were used to detect the expression of NOX2 in 55 primary osteo-sarcoma specimens and in 20 non-neoplastic bone tissue specimens. The correlations between NOX2 expression and clinicopathological parameters were analysed by using the chi(2) test or Fisher's exact test. Disease free survival and overall survival of osteosarcoma patients were assessed by using the Kaplan-Meier method and Cox proportional hazards model. Results: NOX2 was over-expressed significantly in osteosarcoma compared with that in non-neoplastic bone tissue, and correlated with progression free survival (P < 0.001) and overall survival (P < 0.001). The over-expression of NOX2 was associated with tumor size (P < 0.001), tumor location (P < 0.001). The Cox analysed shown that the over-expression of NOX2 was predicted to be worse PFS (hazard ratio (HR) = 4.10, P = 0.004) and OS (hazard ratio (HR) = 3.50, P = 0.010) time in osteosarcoma patients. Conclusions: The results of our study suggest that the over-expression of NOX2 is related to adverse clinical outcome, and can be viewed as an independent prognostic marker in osteosarcoma. Further research is required to verify the predictive value of NOX2 in osteosarcoma patients. (C) 2020 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?